"Aurigene Pharmaceutical Services Ltd Launches Biologics Facility in Genome Valley, Hyderabad"

Aurigene Pharmaceutical Services Limited, a subsidiary of Dr. Reddy's Laboratories Limited, has unveiled its latest biologics facility spanning across 70,000 sq.ft. in Genome Valley, Hyderabad, India. This cutting-edge facility is strategically positioned within the bio cluster of Genome Valley and is dedicated to providing process & analytical development as well as small-scale manufacturing services for antibodies and other recombinant proteins, catering to preclinical and early phase clinical requirements.

While the process and analytical development laboratories are already operational, the commissioning of manufacturing capacity is slated for completion later in 2024.

Equipped with state-of-the-art technology and control systems, the facility boasts a seasoned talent pool ensuring a seamless transition to large-scale commercial CGMP manufacturing facilities. This facility supplements Aurigene's existing discovery capabilities and infrastructure, which primarily focuses on recombinant proteins, including monoclonal antibodies (mAbs), bi-specifics, multi-specifics, immune-fusion molecules, antibody drug conjugates, and other complex proteins.

Aurigene now offers a comprehensive end-to-end service portfolio encompassing solutions from discovery through large-scale commercial manufacturing across three proximally located campuses. This ensures a seamless journey from concept to commercialization. The Genome Valley facility aims to provide robust, compliant, and economically viable cell lines, process development solutions, and supporting analytical methods for customers seeking rapid progression through clinical development.

The inauguration of this new facility aligns with Aurigene's strategic initiatives to bolster growth in both small molecule and biologics sectors, as demonstrated by recent endeavors in AI/ML-led drug discovery in small molecules and a collaboration with Vipergen, a DNA-encoded library (DEL) technologies service provider.

Akhil Ravi, CEO of Aurigene, expressed his satisfaction with the facility's operationalization, emphasizing the company's steadfast commitment to expanding its biologics business. He highlighted the facility's capacity and capabilities as a testament to Aurigene's 25 years of proven experience, aiming to efficiently serve global customers and contribute to innovative medicine development.

Dr. Roger Lias, Global Commercial Head - Biologics at Aurigene, emphasized the facility's role in supporting customers' end-to-end needs, from discovery services to large-scale commercial manufacture of both Drug Substance and Drug Product. He underscored Aurigene's commitment to technical excellence, global compliance, and state-of-the-art facilities, catering to the evolving needs of biotech start-ups and global pharmaceutical companies alike.

EQUITYBULLS